TICKERNERD
Menu
LMRIHealthcare · Medical Devices

LMRI Stock Forecast: Lumexa Imaging Holdings, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$12
−4.59% on the day

The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. hold a median 12-month price target of $17 — +43.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
2 / 100
Median analyst target
$17
Analysts covering
8
Revenue$252.5M+1.8% y/y
Operating income$4.5M
Net income$1.7M
Free cash flow−$2.4M
Quarterly, 5 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
+8.4%
YTD
−35.9%
From high
−36.0%
From low
+75.0%
$7
$19
Range since 11 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

LMRI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lumexa Imaging Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
69
Size
43
Growth
8
Accruals
8
Value
7
Momentum
2
Volatility
2
Quality
1
Issuance
1

Revisions (69): Analysts have, on balance, been raising their forecasts.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LMRI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LMRI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 11 Dec 2025Adjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26LMRIHigh $23Median $17Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $9Median $17High $23

The green dot is the last close — the median target sits +43.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026BarclaysMaintainsOverweight$15 → $9.00
14 Apr 2026BarclaysMaintainsOverweight—
9 Feb 2026Raymond JamesUpgradeStrong Buy—
5 Jan 2026BarclaysInitiatesOverweight—
5 Jan 2026Deutsche BankInitiatesBuy—
5 Jan 2026JefferiesInitiatesBuy—
5 Jan 2026Leerink PartnersInitiatesOutperform—
5 Jan 2026Raymond JamesInitiatesOutperform—
5 Jan 2026Wells FargoInitiatesOverweight—
5 Jan 2026William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMRI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LMRI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

LMRI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26LMRIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LMRI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+11.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Lumexa Imaging Holdings, Inc. (LMRI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.8×

Cheaper than 96% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
26.8×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
5.1%

Higher than 39% of US stocks

Earnings growth (YoY)
—
Gross margin
13.8%

Higher than 13% of US stocks

Operating margin
3.2%

Higher than 51% of US stocks

Net margin
−2.7%

Higher than 27% of US stocks

Returns & dividend
Return on equity
−8.0%

Higher than 37% of US stocks

Return on assets
−2.7%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lumexa Imaging Holdings, Inc. (LMRI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lumexa Imaging Holdings, Inc. has a market value of $1.2B and an enterprise value of $2.1B.

  • Shares outstanding: 96.1M.

  • Trailing P/E: −18.8×; forward P/E: 13.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lumexa Imaging Holdings, Inc. employs 5,000 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

LMRI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LMRILumexa Imaging Holdings, Inc.$1.2B
2
BVSBioventus, Inc.$1.2B
98
PRCTPROCEPT BioRobotics Corp.$1.2B
38
IRMDIRadimed Corp.$1.1B
92
IARTIntegra LifeSciences Holdings Corp.$1.3B
90
AORTArtivion, Inc.$1.4B
45
QDELQuidelOrtho Corp.$1.0B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lumexa Imaging Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LMRI news & analysis

Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?

Zacks Investment Research · 24 Aug 2026positive

Wall Street analysts' consensus price target implies a roughly 36.9% upside potential for Lumexa (LMRI), though the article notes this metric is not highly effective. It also points to an upward trend in earnings estimate revisions as a possible near-term positive signal for the stock.

Why it matters — A Lumexa watcher would care because the analyst consensus target and upward earnings estimate revisions point to possible upside for the stock in the near term.

Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Lumexa Imaging Holdings, Inc. (LMRI) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The brief item indicates the earnings call transcript is now available to readers.

Why it matters — A LMRI watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 results and management commentary.

Lumexa Imaging Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

Lumexa Imaging reported second-quarter revenue growth, higher advanced-imaging volumes, and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reaffirming its revenue and adjusted EPS guidance.

Why it matters — The return to profitability and narrowed EBITDA outlook signal improved financial discipline, while the reaffirmed guidance offers LMRI watchers a steady view of the company's near-term expectations.

Lumexa Imaging Announces Second Quarter 2026 Results

GlobeNewsWire · 12 Aug 2026neutral

Lumexa Imaging reported financial results for its second quarter ended June 30, 2026, and updated its full-year 2026 outlook in an announcement made on August 12, 2026.

Why it matters — This release updates LMRI watchers on the company's quarterly performance and revised expectations for the full year, key indicators of how the outpatient imaging business is tracking.

Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date

GlobeNewsWire · 29 July 2026neutral

Lumexa Imaging announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.

Why it matters — The announcement signals the upcoming release of key financial and operational data that will provide insight into the company's recent performance.

FAQ

Frequently asked questions about LMRI stock

What is the LMRI stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. have a median 12-month price target of $17, with estimates ranging from $9 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LMRI stock a buy right now?

Of the 8 analysts covering Lumexa Imaging Holdings, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lumexa Imaging Holdings, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LMRI?

As at 22 Aug 2026, Lumexa Imaging Holdings, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (69 of 100).

Will LMRI stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +43.5% from the last close, and Ticker Nerd's factor model ranks Lumexa Imaging Holdings, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LMRI stock forecast for 2030?

No analyst covering Lumexa Imaging Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $23 over the next 12 months.

What does Lumexa Imaging Holdings, Inc. do?

Lumexa Imaging Holdings, Inc. is a healthcare services company that owns and operates outpatient diagnostic imaging centers across the United States.

What is the latest news on LMRI?

The most recent item we track (Zacks Investment Research, 24 Aug 2026): "Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?". Wall Street analysts' consensus price target implies a roughly 36.9% upside potential for Lumexa (LMRI), though the article notes this metric is not highly effective. It also points to an upward trend in earnings estimate revisions as a possible near-term positive signal for the stock.

Company

About Lumexa Imaging Holdings, Inc.

Lumexa Imaging Holdings, Inc. is a healthcare services company that owns and operates outpatient diagnostic imaging centers across the United States. The company focuses on providing a broad range of medical imaging procedures, including magnetic resonance imaging, computed tomography, positron emission tomography, X-ray, ultrasound, and mammography for both diagnostic and screening purposes. Lumexa Imaging Holdings, Inc. plays a key role in the outpatient care ecosystem by offering advanced imaging capabilities in lower-cost, non-hospital settings, supporting physicians, health systems, and patients with accessible imaging options. Formed in 2018 in partnership with Charlotte Radiology and private equity firm Welsh, Carson, Anderson & Stowe, it has grown into one of the largest national providers of diagnostic imaging services, operating over a hundred centers in multiple states. Headquartered in Raleigh, North Carolina, the company emphasizes clinical quality, state-of-the-art technology, and an integrated platform designed to scale across diverse regional markets.

CEO Ms. Caitlin Zulla · 5,000 employees · United States · https://www.lumexaimaging.com